<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>2024</volume><submitter>Wang Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Colitis is a refractory intestinal inflammatory disease significantly affecting the quality of a patient's life and increasing the risk of exacerbation. The primary factors leading to colitis encompass infections, insufficient blood flow, and the buildup of collagen as well as white blood cells. Among various available therapeutics, 5-methoxytryptophan (5-MTP) has emerged as one of the protectants by inhibiting inflammatory damage. Nonetheless, there is no report on the role of 5-MTP in the treatment of colitis.&lt;h4>Materials and methods&lt;/h4>To verify the anti-inflammatory effect of 5-MTP &lt;i>in vivo&lt;/i>, we first constructed mouse model with dextran sulfate sodium-induced colitis. Furthermore, the macrophage infiltration and release of inflammatory factors through western</pubmed_abstract><journal>Mediators of inflammation</journal><pagination>1484806</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11390199</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>5-Methoxytryptophan Alleviates Dextran Sulfate Sodium-Induced Colitis by Inhibiting the Intestinal Epithelial Damage and Inflammatory Response.</pubmed_title><pmcid>PMC11390199</pmcid><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Cheng F</pubmed_authors><pubmed_authors>Zhu Z</pubmed_authors><pubmed_authors>Cheng P</pubmed_authors><pubmed_authors>Zhao F</pubmed_authors><pubmed_authors>Yang Q</pubmed_authors><pubmed_authors>Zhao D</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Ai X</pubmed_authors></additional><is_claimable>false</is_claimable><name>5-Methoxytryptophan Alleviates Dextran Sulfate Sodium-Induced Colitis by Inhibiting the Intestinal Epithelial Damage and Inflammatory Response.</name><description>&lt;h4>Background&lt;/h4>Colitis is a refractory intestinal inflammatory disease significantly affecting the quality of a patient's life and increasing the risk of exacerbation. The primary factors leading to colitis encompass infections, insufficient blood flow, and the buildup of collagen as well as white blood cells. Among various available therapeutics, 5-methoxytryptophan (5-MTP) has emerged as one of the protectants by inhibiting inflammatory damage. Nonetheless, there is no report on the role of 5-MTP in the treatment of colitis.&lt;h4>Materials and methods&lt;/h4>To verify the anti-inflammatory effect of 5-MTP &lt;i>in vivo&lt;/i>, we first constructed mouse model with dextran sulfate sodium-induced colitis. Furthermore, the macrophage infiltration and release of inflammatory factors through western</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2025-04-04T02:49:18Z</modification><creation>2025-04-04T02:49:18Z</creation></dates><accession>S-EPMC11390199</accession><cross_references><pubmed>39262415</pubmed><doi>10.1155/2024/1484806</doi></cross_references></HashMap>